Innate's Lirilumab In Limbo After Phase II Combo Failure
Bristol-Myers Squibb and Innate Pharma's anti-KIR monoclonal antibody lirilumab has failed to show efficacy in a combination trial with Opdivo in head and neck cancer – further development of the doublet treatment in solid tumors now seems unlikely.
You may also be interested in...
France's Innate Pharma gets a boost to its plans to become a fully integrated biotech by forging a long-term immuno-oncology development partnership with AstraZeneca, and the setting up of a commercialization team in the US.
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.
Rising Leader Yolanda Tibbe, Novartis’s head of new commercial partnerships in Germany, talks about transformation at the Swiss big pharma and how to put ‘patients as customers’ thinking into action.